

RECEIVED

AUG 13 2003

1617

TECH CENTER 1600/2000

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	08/071,052
	Filing Date	Jun 4, 1993
	First Named Inventor	Kreamer
	Art Unit	1617
	Examiner Name	Criares, Theodore J
Total Number of Pages in This Submission	Attorney Docket Number	4673120/4650


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group ( <b>Appeal Notice, Brief, Reply Brief</b> ) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Kent A. Herink
Signature	<i>Kent A. Herink</i>
Date	<i>August 7, 2003</i>

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: <i>8-7-03</i>			
Type or printed	Jeri D. Krutsinger		
Signature	<i>Jeri D. Krutsinger</i>	Date	<i>8-7-03</i>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
Jeffery W. Kreamer ) Group Art Unit 1617  
Serial No. 08/071,052 ) Examiner: T. Criares  
Filed: June 4, 1993 )  
For: ASPIRIN AND VITAMIN )  
AND/OR TRACE ELEMENT )  
COMPOSITIONS FOR THE )  
TREATMENT OF VASCULAR )  
DISEASE )

#42  
mp  
9/4/03  
N.E

REQUEST FOR RECONSIDERATION

In response to the communication mailed July 24, 2003 and received July 28, 2003, the Applicant respectfully submits the following request for reconsideration, accompanied by an additional copy of the requested published University of California study.

Based on the foregoing, the Applicant respectfully submits that its claims are in condition for allowance at this time. Accordingly, reconsideration of the application and passage to allowance are respectfully solicited.

The Examiner is respectfully urged to call the undersigned attorney at (515) 288-2500 to discuss the claims in an effort to reach a mutual agreement with respect to claim limitations in the present application which will be effective to define the patentable subject matter if the present claims are not deemed adequate for this purpose.

Respectfully Submitted,

Date:

August 6, 2003

Kent A. Herink

Kent A. Herink

Registration No. 31,025

DAVIS, BROWN, KOEHN,  
SHORS & ROBERTS, P.C.

666 Walnut St., Suite 2500

Des Moines, Iowa 50309

Telephone: (515) 288-2500

ATTORNEYS FOR APPLICANT

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
first class mail in an envelope addressed to:  
Assistant Commissioner for Trademarks, 2900  
Crystal Drive, Arlington, Virginia 22202-3513, on

August 7, 2003

By

Jeri D. Krutinger

## Aspirin use and chronic diseases: a cohort study of the elderly

Annlia Paganini-Hill, Ann Chao, Ronald K Ross, Brian E Henderson

## Abstract

**Objective**—To evaluate the associations between the use of aspirin and the incidences of cardiovascular diseases, cancers, and other chronic diseases.

**Design**—Postal questionnaire survey to elicit details of aspirin use.

**Setting**—Californian retirement community.

**Subjects**—All 22781 residents of the community (white, affluent, and well educated) were sent a questionnaire that included questions on medical history and the use of drugs such as analgesics, laxatives, and vitamin supplements. In all 61% responded (13987, 8881 women and 5106 men; median age 73). They formed the cohort that was followed up for 6½ years using discharge summaries from three hospitals serving the area and death certificates from the health department. Only 13 respondents were lost to follow up but seemed not to have died.

**Main outcome measures**—Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily.

**Results**—Age adjusted incidences were computed with an internal standard and five age groups. By 1 January 1988 there had been 25 incident cases of kidney cancer among all participants; 341 incident cases of stroke, 253 of acute myocardial infarction, 220 of ischaemic heart disease, and 317 of other heart disease were reported among respondents without a reported history of angina, myocardial infarction, or stroke. The incidence of kidney cancer was raised among those who took aspirin daily compared with those who did not take it, although the increase was significant only in men (relative risks=6.3, 95% confidence interval 2.2 to 17, for men and 2.1, 0.53 to 8.5, for women). Those who took aspirin daily showed no increased risk of any other cancer, except colon cancer for both sexes combined (relative risk=1.5, 1.1 to 2.2). The risk of acute myocardial infarction was reduced slightly among regular users of aspirin in men but not women. The risk of ischaemic heart disease was almost doubled in those who took aspirin daily compared with non-users (relative risks=1.9, 1.1 to 3.1, for men and 1.7, 1.1 to 2.7, for women). Small, non-significant increased risks of stroke were observed in both sexes.

**Conclusion**—The daily use of aspirin increased the risk of kidney cancer and ischaemic heart disease.

## Introduction

In the United States vascular diseases account for about 1.2 million deaths, or half of all deaths each year. Recently, the results of a large clinical trial showing that regular use of aspirin may prevent myocardial

infarction have received widespread publicity. Given the preliminary nature of this published report, the limitation of the study to men, some evidence of internal inconsistency of the results, and the contradictory findings of other trials, this relation cannot yet be considered secure.

As part of a prospective study on lifestyle practices and disease prevention in a retirement community in southern California, we assessed the association between regular use of analgesics containing aspirin and the incidence of several chronic diseases, including cardiovascular diseases and cancer.

## Methods

In June 1981 a detailed health questionnaire was sent to all residents of Leisure World, Laguna Hills, a retirement community near Los Angeles, California. New residents who moved into the community after this date were sent the questionnaire in June 1982, June 1983, and October 1985. Residents of this community are almost always white, moderately affluent, and well educated, and about two thirds are women.

The health questionnaire requested information on previous medical diagnoses, including angina, acute myocardial infarction, hypertension, rheumatoid arthritis, and diabetes; height and weight; the use of drugs, including analgesics, laxatives, and vitamin supplements; the use of cigarettes and alcohol; exercise habits; dietary intake of certain foods; and for women menstrual and reproductive events, including use of oestrogen replacement treatment. The use of analgesics was ascertained from the questions: "Which of the following best describes your use of non-prescription pain medication? Several times a day, daily, weekly, monthly, less often or never" and "When you take non-prescription pain medication, what is the brand (for example, Empirin, Anacin, Bayer Aspirin) you usually take?"

The cohort was followed up for all hospital admissions to three hospitals serving the area (85% of these occur at one hospital immediately adjacent to the community) and for deaths with the death certificate records of the local health department. Death certificates were also obtained for those who had died and been identified by the community business office, from the obituary column of the local newspaper, and from information provided by relatives and friends. In addition, we conducted two postings of follow up questionnaires to the cohort in 1983 and 1985. To date only 13 members of the cohort have been lost to follow up; search of the National Death Index (a computerised register of death record information maintained by the National Center for Health Statistics) did not show that these people had died.

The members of the cohort were followed up to the time of the event of interest (admission to hospital) or death or to 1 January 1988, whichever came first. Age

Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033-0800, United States.

Annlia Paganini-Hill, PhD, professor

Ann Chao, MS, statistical analyst

Ronald K Ross, MD, professor

Brian E Henderson, MD, professor

Correspondence to: Dr Paganini-Hill.

Br Med J 1989;299:1247-50

adjusted relative risks using five age groups (<75, 75-79, 80-84, 85-89,  $\geq 90$ ) and p values were obtained with a regression method that assumed that the development of cancer or chronic disease could be regarded as a Poisson process with a constant hazard rate for a given person.<sup>13</sup> The generalised linear interactive modelling (GLIM) software package program was used to make these calculations.<sup>14</sup> All reported p values are two-sided.

## Results

The residents' median age was 73. After three postings 13 987 residents (61% of the 22 781 residents) returned questionnaires; 8881 of the respondents were women. The distribution of sex was comparable in respondents and non-respondents, but the non-respondents were slightly older; overall mortality was greater in non-respondents in the first few years of follow up and then became identical with that in the respondents.

By 1 January 1988 the 8881 women and 5106 men in the cohort had contributed over 42 000 and 25 000 person years of follow up, respectively. The incidence of kidney cancer was increased among daily users of aspirin in both men and women, although the result was significant only in the men (table I). This increase was more evident for renal cell carcinomas (sex and age adjusted relative risk = 6.3, 95% confidence interval 2.0 to 20,  $p < 0.01$ , for daily aspirin users compared with non-users) than for transitional cell cancers (relative risk = 2.2, 0.65 to 7.6,  $p = 0.20$ ).

Colon cancer showed some increased risk with the use of aspirin in both sexes (table I). The result was significant in both sexes combined (sex and age adjusted relative risk = 1.5, 1.1 to 2.2,  $p < 0.05$  for daily aspirin users compared with non-users). The increased risk was not restricted to a particular segment of the colon (data not shown). No other strong or significant cancer associations were apparent between the regular use of aspirin and the development of any other cancer.

TABLE I—Numbers of cases and age adjusted relative risks for incidence of cancer by sex and use of analgesics containing aspirin

Aspirin use	Colon		Lung		Bladder		Kidney		Prostate or breast	
	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk
Men:										
None (n=3490)	47	1.00	46	1.00	55	1.00	6	1.00	108	1.00
<Daily (n=685)	13	0.73	8	0.87	4	0.37			18	0.90
Daily (n=876)	19	1.67	15	1.35	15	1.12	9	6.28*	25	0.95
Women:										
None (n=6021)	66	1.00	32	1.00	14	1.00	6	1.00*	146	1.00
<Daily (n=1417)	15	0.95	8	1.00	5	1.56	1	0.72	33	0.95
Daily (n=1380)	21	1.41	2	0.29	3	0.89	3	2.11	35	0.96

\* $p < 0.05$ .

TABLE II—Numbers of cases and age adjusted relative risks for incidence of cardiovascular diseases (excluding people with reported history of angina, acute myocardial infarction, and stroke) by sex and use of analgesics containing aspirin

Aspirin use	Total (ICD 390-438)		Stroke (ICD 430-434, 436)		Acute myocardial infarction (ICD 410-414)		Ischaemic heart disease (ICD 411-414)		Other heart disease (ICD 402, 424, 425, 428, 429, 440, 441)	
	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk
Men:										
None (n=2587)	406	1.00	101	1.00	98	1.00	54	1.00	87	1.00
<Daily (n=529)	80	1.02	16	0.87	13	0.64	17	1.51	21	1.25
Daily (n=516)	113	1.46*	26	1.22	14	0.73	19	1.86*	29	1.64
Women:										
None (n=5169)	568	1.00	135	1.00	86	1.00	77	1.00	124	1.00
<Daily (n=1207)	122	0.97	26	0.88	22	1.16	25	1.45	23	0.85
Daily (n=1063)	166	1.39*	37	1.27	20	1.06	28	1.72*	33	1.21

\* $p < 0.05$ .

ICD = International Classification of Diseases (ninth revision).

For analyses of the relation between cardiovascular disease and use of aspirin we excluded 1432 men and 1394 women who had reported a history of angina, myocardial infarction, or stroke in the initial survey (table II). The incidence of ischaemic heart disease was raised among daily users of aspirin compared with non-users among both men and women (relative risk = 1.9, 1.1 to 3.1,  $p < 0.05$  and 1.7, 1.1 to 2.7,  $p < 0.05$ , respectively). Except for "other heart disease" (including various diseases, the numerically most important of which was heart failure) in men, the use of aspirin was not significantly related to any other vascular disease examined. A 20-30% increased risk of stroke was, however, seen in men and women who took aspirin daily, but neither of these results was significant (sex and age adjusted relative risk = 1.3, 0.96 to 1.7,  $p = 0.10$  for daily aspirin users compared with non-users). For all cardiovascular diseases combined the risk was raised among daily users of aspirin compared with non-users among both men and women (relative risks = 1.5, 1.2 to 1.8,  $p < 0.05$  and 1.4, 1.2 to 1.7,  $p < 0.05$ , respectively).

Other chronic diseases examined because of previous evidence of a possible association with regular use of aspirin included gastrointestinal bleeding, gastric ulcers, and cataracts (table III). Among women, those who used aspirin less than daily showed a significant reduction in risk for ulcers (relative risk = 0.3, 0.14 to 0.74,  $p < 0.05$ ), but there was no evidence of a dose-response effect. No other result was significant or substantially different from unity.

TABLE III—Numbers of cases and age adjusted relative risks for incidence of other diseases by sex and use of analgesics containing aspirin

Aspirin use	Gastrointestinal bleeding		Ulcers		Cataracts	
	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk
Men:						
None (n=3490)	37	1.00	53	1.00	130	1.00
<Daily (n=685)	5	0.73	13	1.26	21	0.83*
Daily (n=876)	13	1.38	13	1.00	39	1.21
Women:						
None (n=6021)	37	1.00	81	1.00	343	1.00
<Daily (n=1417)	8	0.95	6	0.32*	63	0.80
Daily (n=1380)	12	1.29	5	0.76	99	1.21

\* $p < 0.05$ .

## Discussion

Five case-control studies of cancer of the renal pelvis<sup>9</sup> and two of renal cell carcinoma<sup>10</sup> have evaluated the association with use of analgesics, and we have reviewed the subject.<sup>11</sup> Two studies conducted by McCredie *et al* in New South Wales suggested a strong association between "regular" use of analgesics and cancer of the renal pelvis in both sexes.<sup>9</sup> The second study suggested that in women this strong association was limited mainly to compounds containing phenacetin. In a study in Minnesota McLaughlin *et al* found 3.9-fold and 3.7-fold excess risks of cancer of the renal pelvis in men and women, respectively, who were regular long-term (>36 months) users of drugs containing phenacetin or paracetamol compared with non-users.<sup>10</sup> Neither result, however, was significant. Our case-control study of cancer of the renal pelvis and ureter suggested that heavy use of analgesics obtained over the counter without a prescription is associated with an increased risk and that the increased risk extends across formulations containing all the main active ingredients of preparations currently used in the United States, including aspirin.<sup>11</sup> The data on renal cell carcinoma are scanty and inconclusive.<sup>12</sup> Our current results are compatible with these published findings for cancer of the renal pelvis and suggest that

an even stronger association may exist between the regular use of aspirin and the development of renal-cell carcinoma.

We are not aware of previous reports of an association between cancer of the colon and aspirin intake. Aspirin causes gastric irritation. In sufficiently high doses and combined with interference in absorption by foodstuffs in the intestinal lumen or through other mechanisms, aspirin might similarly affect the large bowel. Such irritation may lead to increased activity of mucosal stem cells, and to an increased risk of cancer.

Evidence that regular administration of aspirin may be beneficial to patients with established coronary heart disease comes from several sources<sup>13-15</sup> and has been recently reviewed by the Antiplatelet Trialists' Collaboration.<sup>16</sup> Overall, in 25 completed randomised trials of antiplatelet treatment (including aspirin) in patients with a history of transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction allocation to antiplatelet treatment reduced mortality from vascular diseases by 15% but had no apparent effect on mortality from non-vascular diseases. There was no significant difference among the effects of the different types of antiplatelet treatment tested (300-325 mg aspirin daily, higher aspirin doses, sulphinpyrazone, or high dose aspirin with dipyridamole) or between the effects in patients with histories of cerebral or cardiac vascular diseases.

There have been two randomised trials of aspirin for the primary prevention of cardiovascular disease. The physicians' health study is a double blind, placebo-controlled trial of 22 071 male doctors in the United States between the ages of 40 and 84. A primary aim of the study is to determine whether 325 mg aspirin taken every other day reduces mortality from and incidence of vascular disease.<sup>17</sup> After an average of 4.8 years of follow up there was no difference between the aspirin and placebo groups in total cardiovascular deaths (relative risk=0.99). The overall mortality from cardiovascular disease was extraordinarily and inexplicably low: 733 deaths expected v 88 observed. The patterns of risk of vascular disease associated with the regular use of aspirin in that study are strikingly similar to the patterns of incidence in men in our study. The physicians' health study observed a 47% reduction in the overall risk of fatal and non-fatal myocardial infarction (relative risk=0.53,  $p<0.00001$ ); we observed a non-significant reduction in risk of myocardial infarction of 36% and 27% among those who took aspirin daily and those who took it less often, respectively. For stroke there was a non-significant increase of 15% among those receiving aspirin in the physicians' health study (relative risk=1.15,  $p=0.41$ ); our results indicate a 22% increase in risk associated with daily aspirin use. For deaths from ischaemic heart disease (data on morbidity were not reported) the relative risk was increased only slightly in the physicians' health study (relative risk=1.08,  $p=0.81$ ) compared with a substantially higher and significant increase observed in our study (relative risk=1.86). We presume, however, that the category "sudden death" in the physicians' health study (relative risk=1.49) includes subjects with underlying ischaemic heart disease. The relative risk for "other" cardiovascular disease deaths (relative risk=1.79) was also quite similar to that in our study (relative risk=1.64).

The only other data on the role of aspirin in the primary prevention of cardiovascular disease derive from a randomised trial of 5139 British doctors that tested 500 mg of aspirin daily.<sup>18</sup> In contrast with the physicians' health study the British data showed no differences in risk of fatal or non-fatal myocardial infarction between those assigned to the aspirin and the control groups. Like the physicians' health study and our study, a slight but non-significant excess of strokes

was observed among those assigned to the aspirin group. No difference was observed in the mortality from all cardiovascular diseases.

Although aspirin treatment has proved benefit for those with a history of cardiovascular disease (secondary prevention), data from the two clinical trials combined with the results from our large prospective study suggest that the risk-benefit equation might balance differently for primary prevention. Though the reduction in mortality from acute myocardial infarction in the physicians' health study was significant, it was accompanied by small increases in mortality from other vascular diseases so that no overall reduction in mortality from vascular diseases was apparent. This observation is supported by data on mortality from the British study and from our data on the incidences of chronic disease. We extend these observations to show no reduction in incidence of vascular disease in women who use aspirin daily. In fact, our study found a significantly increased incidence of ischaemic heart disease in regular aspirin users of both sexes and an increased incidence of "other" heart disease, which was significant in men.

Gastrointestinal discomfort and bleeding and gastric ulcers are established hazards of aspirin use, especially in high doses.<sup>19-22</sup> In a resurvey of a sample of our cohort who took analgesics daily we found that a quarter of the 190 respondents avoided analgesics containing aspirin because of a history of ulcers or stomach problems. If such people at high risk avoid taking aspirin the risk of ulcers in aspirin users would be reduced, as observed in our study.

The use of aspirin has been reported to be protective for cataracts in studies of patients with rheumatoid arthritis,<sup>23</sup> diabetic patients,<sup>24</sup> and patients admitted for cataract extraction.<sup>25,26</sup> Other studies have not, however, confirmed this effect,<sup>27,28</sup> and we see no apparent protection in our cohort despite a substantial number of cases.

Although our data on use of analgesics are self reported, we have evidence that these data are reliable.<sup>9</sup> In the resurvey conducted in 1988 of 190 respondents who took analgesics daily 132 (69%) were still taking an analgesic every day. For these 132 the primary reasons for taking an analgesic were reported to be for arthritis (61 (46%)); for prevention of heart disease, angina, and stroke and as a blood thinner (30 (23%)); and for headache (7 (5%)).

This work was supported by grants CA32197 and CA17054 from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland. We thank Mary Arthur and Beverly Ducey, research staff, for their help, and the residents of Leisure World, Laguna Hills, California, whose cooperation made this work possible.

1. Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1988;318:262-4.
2. Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. *Journal of the American Statistical Association* 1983;78:1-12.
3. Fromme EL. The analysis of rates using Poisson regression models. *Biometrics* 1983;39:665.
4. Baker RJ, Nelder JA. *The GLIM system release 3*. Oxford: Numerical Algorithms Group, 1978.
5. Armstrong B, Garrod A, Doll R. A retrospective study of renal cancer with special reference to coffee and animal protein consumption. *Br J Cancer* 1976;33:127-36.
6. McCredie M, Ford JM, Taylor JS, Stewart JH. Analgesics and cancer of the renal pelvis in New South Wales. *Cancer* 1982;49:2617-25.
7. McCredie M, Stewart JH, Ford JM, MacLennan RA. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. *Br J Urol* 1983;55:220-4.
8. McLaughlin JK, Blot WJ, Mandel JS, Schuman LM, Mehl ES, Fraumeni JF Jr. Etiology of cancer of the renal pelvis. *JNCI* 1983;71:287-91.
9. Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE. Analgesics, cigarette smoking and other risk factors for cancer of the renal pelvis and ureter. *Cancer Res* 1989;49:1045-9.
10. McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF Jr. A population-based case-control study of renal cell carcinoma. *JNCI* 1984;72:275-84.
11. Paganini-Hill A, Ross RK, Henderson BE. Epidemiology of renal cancer. In:

- Stanner DG, Lieberman G, eds. *Diagnosis and management of genitourinary cancer*. Philadelphia: JB Saunders, 1988:329.
- 12 Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. *Br Med J* 1974;3:440-3.
- 13 Elwood PC, Cochran AL, Burr ML, et al. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. *Br Med J* 1974;3:436-40.
- 14 Coronary Drug Project Research Group. Aspirin in coronary heart disease. *J Chronic Dis* 1978;29:625-42.
- 15 Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. *JAMA* 1980;243:661-9.
- 16 Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. *Br Med J* 1988;296:320-31.
- 17 Young FH, Nightingale, Temple RA. The preliminary report of the finding of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction. *JAMA* 1988;259:3158-60.
- 18 Peto R, Gray R, Collins R, et al. A randomised trial of the effects of prophylactic daily aspirin among male British doctors. *Br Med J* 1988;296:313-6.
- 19 Belton MC, Rooney PJ, Tagwell P. Aspirin and gastrointestinal haemorrhage: a methodologic assessment. *J Chronic Dis* 1985;38:101-11.
- 20 Piper DW, McInnes JH, Arforn DE, Fenton BH, MacBennan R. Analgesic ingestion and chronic peptic ulcer. *Gastroenterology* 1981;80:127-32.
- 21 McInnes JH, Byth B, Piper DW. Environmental factors in aetiology of chronic gastric ulcer: a case control study of exposure variables before the first symptoms. *Gut* 1982;26:789-93.
- 22 Faulkner G, Pritchard J, Samerville K, Langman MJS. Aspirin and bleeding peptic ulcers in the elderly. *Br Med J* 1988;297:1311-3.
- 23 Gotlier E. Aspirin and senile cataract in rheumatoid arthritis. *Lancet* 1981;336:9.
- 24 Gotlier E. Senile cataract: evidence for acceleration by diabetes and deceleration by salicylate. *Can J Ophthalmol* 1981;16:113-8.
- 25 Van Heyningen R, Harding JJ. Do aspirin-like analgesics protect against cataract? *Lancet* 1986;331:111-3.
- 26 Gotlier E. Rheumatoid arthritis and cataract surgery. *Int Ophthalmol* 1980;127-9.
- 27 Seigel D, Sperduto RD, Ferris FL III. Aspirin and cataracts. *Ophthalmology* 1982;89:788A.
- 28 West SK, Munoz BE, Newland HS, Emmett EA, Taylor HR. Lack of evidence for aspirin use and prevention of cataracts. *Arch Ophthalmol* 1987;105:1229-31.
- 29 Kewitz H, Nitz M, Gans V. Aspirin and cataract. *Lancet* 1986;336:689.
- 30 Papantoniou AA, Rose RK. Reliability of recall of drug usage and other health related information. *Am J Epidemiol* 1982;116:114-22.

(Accepted 15 September 1989)

## Perinatal transmission of HIV-I in Zambia

S K Hira, J Kamanga, G J Bhat, C Mwale, G Tembo, N Luo, P L Perine

### Abstract

**Objective**—To determine the occurrence of vertical transmission of HIV-I from women positive for the virus and the prognosis for their babies.

**Design**—Women presenting in labour were tested for HIV-I. Their newborn babies were also tested. Women positive for the virus were followed up with their babies for two years.

**Setting**—Teaching hospital in Lusaka, Zambia.

**Subjects**—1954 Women, of whom 227 were seropositive. Of 205 babies, 192 were positive for HIV-I. After birth 109 seropositive mothers and their babies and 40 seronegative mothers and their babies were available for follow up.

**Main outcome measures**—Serological examination of mothers and their babies by western blotting. Birth weight and subsequent survival of babies. Women and babies were tested over two years for signs of seroconversion and symptoms of infection with HIV, AIDS related complex, and AIDS.

**Results**—Of the 109 babies born to seropositive mothers and available for follow up, 18 died before 8 months, 14 with clinical AIDS. Of the 91 remaining, 23 were seropositive at 8 months. By 24 months 23 of 86 surviving babies were seropositive, and a further five infected babies had died, four were terminally ill, 17 had AIDS related complex, and two had no symptoms. The overall rate of perinatal transmission was 42 out of 109 (39%). The overall mortality of infected children at 2 years was 19 out of 42 (44%). Before the age of 1 year infected children had pneumonia and recurrent coughs, thereafter symptoms included failure to thrive, recurrent diarrhoea and fever, pneumonia, candidiasis, and lymphadenopathy. All babies had received live attenuated vaccines before 8 months with no adverse effects.

**Conclusions**—Vertical transmission from infected mothers to their babies is high in Zambia and prognosis is poor for the babies. Perinatal transmission and paediatric AIDS must be reduced, possibly by screening young women and counselling those positive for HIV-I against future pregnancy.

### Introduction

HIV-I may be transmitted from an infected mother to her fetus during pregnancy or childbirth.<sup>1,2</sup> Various

studies estimate that about 20-50% of infants born of infected mothers are also infected.<sup>3,4</sup> We studied the incidence of vertical transmission of HIV-I in Lusaka, Zambia, and the possible risks of immunising potentially infected infants with attenuated vaccines.

### Patients and methods

During February to May 1987, 1954 consecutive women delivering at this hospital were entered in the study. We obtained detailed histories after getting informed consent and performed a thorough physical examination and collected 3-5 ml venous blood. Cord blood was taken from live and stillborn infants. The serum samples of mother, baby, and, in some cases, the father were tested for antibodies to HIV-I by enzyme linked immunosorbent assay (ELISA) and western blot analysis. We attempted to trace and follow up two groups: (a) all women positive for antibody to HIV-I and their infants and (b) 40 sets of women negative for antibody to HIV-I and their infants. All seropositive women and their spouses were counselled. Repeat venous blood samples were collected from mothers and infants in both the groups at 6-8, 12, 18, and 24 months and tested for antibodies to HIV and a complete blood count was done. All children received vaccines: BCG at birth, oral polio and diphtheria, pertussis, and tetanus at 3, 4, and 5 months, and measles at 8 months.

Data were analysed by using  $\chi^2$  tests with epidemiologic software from the Centers for Disease Control.

### Results

Of 1954 women screened at delivery, 227 (12%) were seropositive for HIV-I. The seropositive women were significantly younger with a mean (SD) age of 23.9 (5.4) years (Student's *t* test  $p < 0.05$ ). The seronegative women had a mean (SD) age of 25.1 (7.7) years. Among seropositive women, 62 (27%) were primigravidae and 185 (82%) were married. Risk cofactors such as higher number of lifetime sexual partners (table I), single or divorced or widowed, higher educational state (table II), history of transfusion, travel abroad, and working (table III) were associated with high seroprevalence of HIV-I. Fifty two (23%) of the seropositive women had adverse outcomes compared with 227 (13%) of the seronegative women

Dermato-Venereology  
Department, University  
Teaching Hospital, Box  
50001, Lusaka, Zambia  
S K Hira, MD, consultant  
J Kamanga, DCMs, clinical  
officer  
C Mwale, DCMs, clinical  
officer

Department of Paediatrics,  
University Teaching  
Hospital, Lusaka  
G J Bhat, MD, senior lecturer

Department of Community  
Medicine, University  
Teaching Hospital, Lusaka  
G Tembo, MBChB, lecturer

Department of Pathology/  
Immunology, University  
Teaching Hospital, Lusaka  
N Luo, PhD, lecturer

Uniformed Services  
University of the Health  
Sciences, Bethesda,  
Maryland, United States  
P L Perine, MPH, professor of  
tropical public health

Correspondence to:  
Dr Hira.

*Br Med J* 1989;299:1250-2